SBRT effective for inoperable early-stage lung cancer.
Updated results from RTOG 0236, a phase II trial examining stereotactic body radiation therapy for inoperable early-stage non-small cell lung cancer, indicate that this treatment continues to yield a high rate of primary tumor control. Compared with conventional radiotherapy, overall survival is also significantly improved.